Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare

692 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$78.00

▲(30.39% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $78.00 with a high forecast of $89.00 and a low forecast of $66.00. The average price target represents a 30.39% change from the last price of $59.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","90":"$90","47.25":"$47.3","61.5":"$61.5","75.75":"$75.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,47.25,61.5,75.75,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.02,54.86461538461539,57.70923076923077,60.55384615384616,63.39846153846154,66.24307692307693,69.08769230769231,71.93230769230769,74.77692307692308,77.62153846153846,80.46615384615384,83.31076923076924,86.15538461538462,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.02,54.018461538461544,56.01692307692308,58.01538461538462,60.01384615384616,62.012307692307694,64.01076923076923,66.00923076923077,68.00769230769231,70.00615384615385,72.00461538461539,74.00307692307692,76.00153846153846,{"y":78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.02,53.09538461538462,54.17076923076923,55.246153846153845,56.321538461538466,57.39692307692308,58.472307692307695,59.54769230769231,60.62307692307692,61.698461538461544,62.77384615384615,63.84923076923077,64.92461538461538,{"y":66,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$89.00

Average Price Target$78.00

Lowest Price Target$66.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$56

Hold

-6.39%

Downside

Reiterated

08/07/25

Mirum Pharmaceuticals' overall stock score is driven by strong earnings call sentiment and positive technical indicators, indicating potential growth. However, financial performance challenges, particularly in profitability and cash flow, weigh down the score. Valuation concerns due to negative earnings and lack of dividends also impact the overall assessment.

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$75→$85

Buy

42.09%

Upside

Reiterated

08/07/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

Jonathan WollebenCitizens JMP

Citizens JMP

$79→$81

Buy

35.41%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMPMirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$73→$80

Buy

33.73%

Upside

Reiterated

08/07/25

Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals

Ryan DeschnerRaymond James

Raymond James

$77→$82

Buy

37.08%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$76→$89

Buy

48.78%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals (MIRM) Gets a Buy from Evercore ISI

Michael UlzMorgan Stanley

Morgan Stanley

$70→$75

Buy

25.38%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Morgan Stanley

Mani ForooharLeerink Partners

Leerink Partners

$56→$66

Buy

10.33%

Upside

Reiterated

08/07/25

Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential

Brian SkorneyRobert W. Baird

Robert W. Baird

$55→$72

Buy

20.36%

Upside

Reiterated

08/07/25

Robert W. Baird Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

David LebowitzCiti

Citi

$68→$72

Buy

20.36%

Upside

Reiterated

05/12/25

Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)

Jessica FyeJ.P. Morgan

J.P. Morgan

$53

Buy

-11.40%

Downside

Reiterated

04/04/25

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$66→$70

Buy

17.02%

Upside

Reiterated

11/12/24

Mirum Pharamceuticals (MIRM) PT Raised to $70 at StifelStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$56

Hold

-6.39%

Downside

Reiterated

08/07/25

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$75→$85

Buy

42.09%

Upside

Reiterated

08/07/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

Jonathan WollebenCitizens JMP

Citizens JMP

$79→$81

Buy

35.41%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMPMirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$73→$80

Buy

33.73%

Upside

Reiterated

08/07/25

Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals

Ryan DeschnerRaymond James

Raymond James

$77→$82

Buy

37.08%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$76→$89

Buy

48.78%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals (MIRM) Gets a Buy from Evercore ISI

Michael UlzMorgan Stanley

Morgan Stanley

$70→$75

Buy

25.38%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Morgan Stanley

Mani ForooharLeerink Partners

Leerink Partners

$56→$66

Buy

10.33%

Upside

Reiterated

08/07/25

Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential

Brian SkorneyRobert W. Baird

Robert W. Baird

$55→$72

Buy

20.36%

Upside

Reiterated

08/07/25

Robert W. Baird Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

David LebowitzCiti

Citi

$68→$72

Buy

20.36%

Upside

Reiterated

05/12/25

Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)

Jessica FyeJ.P. Morgan

J.P. Morgan

$53

Buy

-11.40%

Downside

Reiterated

04/04/25

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$66→$70

Buy

17.02%

Upside

Reiterated

11/12/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

1 Month

xxx

Success Rate

16/33 ratings generated profit

Average Return

+2.64%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.48% of your transactions generating a profit, with an average return of +2.64% per trade.

3 Months

xxx

Success Rate

21/33 ratings generated profit

Average Return

+7.19%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +7.19% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

16/16 ratings generated profit

Average Return

+38.81%

reiterated a buy rating 2 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +38.81% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+78.11%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +78.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 78.00.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.18 with a range of -$0.33 to -$0.03. The previous quarter’s EPS was -$0.12. MIRM beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $127.15M with a range of $114.00M to $134.16M. The previous quarter’s sales results were $127.78M. MIRM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 78.00.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals Inc has 30.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals Inc’s price target?

The average price target for Mirum Pharmaceuticals Inc is 78.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $89.00 ,the lowest forecast is $66.00. The average price target represents 30.39% Increase from the current price of $59.82.

What do analysts say about Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts